| Elaine C Siegfried, MD | |
|
1465 S Grand Blvd, Saint Louis, MO 63104-1003 | |
| (314) 577-3450 | |
| (314) 268-4077 |
| Full Name | Elaine C Siegfried |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Location | 1465 S Grand Blvd, Saint Louis, Missouri |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508975160 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 101877 (Missouri) | Primary |
| Entity Name | Ssm Health Care Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306589544 PECOS PAC ID: 0143608372 Enrollment ID: O20220531002655 |
News Archive
Today, about half the world's population lives in areas at risk of malaria transmission. The disease is transmitted to humans through bites from mosquitoes, and each year causes hundreds of thousands of deaths worldwide, with about 1,500 of these in the United States.
In an analysis from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, one of the largest studies of its kind to determine whether intensive blood glucose (sugar) control worked better than standard blood sugar control among diabetics, results show that the benefits of intensive therapy need to be balanced against the increase in total and cardiovascular disease-related death, increased weight gain, and high risk for severe low blood sugar.
Data from four pivotal Phase III clinical trials demonstrate that linagliptin achieved statistically significant and sustained reductions in blood sugar as measured by hemoglobin A1c, fasting plasma glucose and postprandial glucose. Boehringer Ingelheim Pharmaceuticals, Inc. is investigating the dipeptidyl peptidase 4 inhibitor as an oral once-daily tablet, as monotherapy and combination therapy, to treat type 2 diabetes.
St. Jude Medical, Inc., a global medical device company, today announced Japanese Ministry of Health, Labour and Welfare approval and reimbursement approval of its Therapy Cool Path Ablation Catheter. This marks the company's first entry into the irrigated catheter ablation market in Japan.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Elaine C Siegfried, MD 1465 S Grand Blvd, Saint Louis, MO 63104-1003 Ph: (314) 577-3450 | Elaine C Siegfried, MD 1465 S Grand Blvd, Saint Louis, MO 63104-1003 Ph: (314) 577-3450 |
News Archive
Today, about half the world's population lives in areas at risk of malaria transmission. The disease is transmitted to humans through bites from mosquitoes, and each year causes hundreds of thousands of deaths worldwide, with about 1,500 of these in the United States.
In an analysis from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, one of the largest studies of its kind to determine whether intensive blood glucose (sugar) control worked better than standard blood sugar control among diabetics, results show that the benefits of intensive therapy need to be balanced against the increase in total and cardiovascular disease-related death, increased weight gain, and high risk for severe low blood sugar.
Data from four pivotal Phase III clinical trials demonstrate that linagliptin achieved statistically significant and sustained reductions in blood sugar as measured by hemoglobin A1c, fasting plasma glucose and postprandial glucose. Boehringer Ingelheim Pharmaceuticals, Inc. is investigating the dipeptidyl peptidase 4 inhibitor as an oral once-daily tablet, as monotherapy and combination therapy, to treat type 2 diabetes.
St. Jude Medical, Inc., a global medical device company, today announced Japanese Ministry of Health, Labour and Welfare approval and reimbursement approval of its Therapy Cool Path Ablation Catheter. This marks the company's first entry into the irrigated catheter ablation market in Japan.
› Verified 5 days ago
Dr. Caroline M Mann, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 969 N Mason Rd, Div Im Dermatology, Ste 220, Saint Louis, MO 63141 Phone: 314-273-3376 Fax: 888-682-0525 | |
Dr. Eva A. Hurst, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 969 N Mason Rd Ste 200, Ste 200, Saint Louis, MO 63141 Phone: 314-996-8810 Fax: 314-996-8775 | |
Shane A Grace, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 12855 N 40 Dr Ste 180, Saint Louis, MO 63141 Phone: 314-878-5599 Fax: 314-392-4290 | |
Dr. Lee S Portnoff, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3009 N Ballas Rd, Ste 310a, Saint Louis, MO 63131 Phone: 314-993-2909 | |
Aibing Mary Guo, M.D. Dermatology Medicare: May Accept Medicare Assignments Practice Location: 1225 S Grand Blvd Fl 3, Saint Louis, MO 63104 Phone: 314-977-3400 Fax: 314-977-7613 | |
Dr. Amy C Musiek, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 4901 Forest Park Ave, Div Im Dermatology, Ste 502, Saint Louis, MO 63108 Phone: 314-273-3376 Fax: 888-665-8309 | |
Dr. Gillian Meade Heinecke, M.D. Dermatology Medicare: Medicare Enrolled Practice Location: 1755 S Grand Blvd, Saint Louis, MO 63104 Phone: 314-256-3430 Fax: 314-256-3431 |